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See related research by Frenette et al., http://ccforum.com/content/18/6/602In a retrospective study by a Canadian team [1], pentas-
tarch infusion was a dose-related independent risk factor
for acute kidney injury (AKI) after cardiac surgery. In a
new retrospective cardiac surgery study by that team [2],
83% of patients received hydroxyethyl starch (HES) 130/
0.4. For unexplained reasons, 25 to 43% of patients
received both HES 130/0.4 and pentastarch.
The team 'hypothesized that both synthetic starches and
albumin-containing solutions are independently associated
with AKI following cardiac surgery in a dose-dependent
fashion'. However, they focused on albumin and never
thoroughly evaluated HES-related AKI. Although univariate
analyses were reported, propensity matching according to
either HES 130/0.4 or pentastarch administration was omit-
ted. Systematic allocation of low-risk patients to HES could
have masked an association with AKI in the univariate ana-* Correspondence: konrad.reinhart@med.uni-jena.de
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unless otherwise stated.lyses. Consequently, the study is misleading, since it sug-
gests that albumin is associated with AKI while HES is not.
We described a prospective study in 6,478 consecutive
cardiac surgery patients [3]. With propensity matching,
predominant use of HES 130/0.4 was associated with
increased utilization of renal replacement therapy: odds
ratio 1.46 and 95% confidence interval (CI) 1.08 to 1.97.
Furthermore, in a meta-analysis of 15 randomized trials
evaluating perioperative HES administration, including
five in cardiac surgery, renal replacement therapy was in-
creased by HES solutions as a class with relative risk 1.44
and CI 1.04 to 2.01 and by HES 130/0.4 in particular (rela-
tive risk 1.47, CI 1.02 to 2.12) [4]. Based on these results
and other currently available data, complete avoidance of
HES solutions such as HES 130/0.4 has been recom-
mended [5].d David R WilliamsonWe agree with Bayer and Reinhart that the administration
of HES solutions should be avoided, based on results from
randomized trials [6,7]. Indeed, we had acknowledged in
the article that HES solutions are an independent risk
factor for AKI [2]. In contrast to what the authors
mentioned, our propensity score included the percentage
and dose of HES administered [2]. In our study, the risk of
AKI appeared higher with albumin than with HES
(Figure three in [2]). Given a recent increase in albumin
use in our institution in light of recent HES publications,
we felt prudent to test whether this finding was artifactual.
Over the past decade, several studies have been published
on the timing [8], duration, type [6], and amount of fluid
[9] to be given in critically ill patients. However, the best
approach regarding fluid resuscitation is still uncertain and
many other questions remain unanswered. When, howmuch, how fast, and how long should we administer which
type of fluid to optimize cardiac output, while minimizing
potential resultant fluid accumulation, tissue edema and
consequent organ dysfunction? As critically ill patients are
a heterogeneous population, a treatment may be beneficial
to one subgroup of patients but harmful to another. Our
study results do not suggest that albumin should never be
administered in cardiac surgery patients. Further studies
are needed to define the best type of fluid (balanced
crystalloids, isotonic saline and albumin), optimal amount,
timing and duration in a priori defined critically and non-
critically ill populations.Abbreviations
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